Tyra Biosciences, Inc. $TYRA Shares Acquired by Strs Ohio

Strs Ohio increased its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 2,485.7% in the first quarter, HoldingsChannel.com reports. The firm owned 18,100 shares of the company’s stock after acquiring an additional 17,400 shares during the quarter. Strs Ohio’s holdings in Tyra Biosciences were worth $693,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Commodore Capital LP increased its holdings in Tyra Biosciences by 8.9% in the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after buying an additional 275,000 shares in the last quarter. HighVista Strategies LLC lifted its position in shares of Tyra Biosciences by 163.6% during the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock valued at $921,000 after acquiring an additional 40,850 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Tyra Biosciences during the 3rd quarter worth approximately $2,612,000. 5AM Venture Management LLC boosted its stake in shares of Tyra Biosciences by 9.6% during the 4th quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after acquiring an additional 90,000 shares in the last quarter. Finally, Fisher Asset Management LLC acquired a new stake in shares of Tyra Biosciences in the 4th quarter worth approximately $757,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Stock Up 2.0%

NASDAQ TYRA opened at $32.57 on Thursday. Tyra Biosciences, Inc. has a fifty-two week low of $9.93 and a fifty-two week high of $40.65. The business has a fifty day moving average of $31.38 and a 200-day moving average of $32.10. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -14.94 and a beta of 0.76.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). As a group, analysts anticipate that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

Analysts Set New Price Targets

TYRA has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a research note on Thursday, May 14th. Canaccord Genuity Group assumed coverage on Tyra Biosciences in a report on Monday, April 6th. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler lifted their price target on Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, March 20th. Guggenheim began coverage on shares of Tyra Biosciences in a research note on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective on the stock. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.